A Randomised, Double-blind, Placebo-controlled, Mono-centre, Explorative Phase II Trial to Study the Effects of Rosuvastatin on Basal Production and Release of Nitric Oxide From the Renal Vasculature in Patients With Hypercholesterolemia.
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Hypercholesterolemia
- Sponsor
- University of Erlangen-Nürnberg Medical School
- Enrollment
- 46
- Locations
- 1
- Primary Endpoint
- Change in renal plasma flow from baseline in response to L-NMMA infusion after 6 weeks treatment with rosuvastatin.
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The endothelium plays an important role in the regulation of vascular tone and regulation of blood flow. Nitric oxide (NO) is the most important known endothelium-derived vasodilating factor. Prospective studies have shown that hypercholesterolemia impairs endothelial function in different vascular beds. Lowering total cholesterol and particularly LDL-cholesterol with statins leads to an improvement in endothelium-dependent vasodilation in the forearm vasculature. There is strong evidence to suggest that the benefit is not merely related to the decrease in cholesterol-levels. A recent study in the forearm vasculature demonstrated that short-term lipid-lowering therapy improves endothelial function and NO availability already after 3 days of lipid lowering therapy. Whether endothelial function in the renal vasculature of hypercholesterolemic patients is similarly influenced has not yet been addressed adequately. In the present study we investigate whether lipid lowering therapy with rosuvastatin alters renal endothelial function, as assessed by systemic infusion of the NO synthase inhibitor L-NMMA, after 3 and 42 days of therapy.
Investigators
Roland E. Schmieder
Prof. Dr. med.
University of Erlangen-Nürnberg Medical School
Eligibility Criteria
Inclusion Criteria
- •Female and male patients aged between 18 and 75 years
- •fasting LDL C concentrations \>=160 and \< 250mg/dl
- •fasting TG concentrations =\< 350mg/dl
Exclusion Criteria
- •History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins).
- •History of hypersensitivity reaction to inulin.
- •Lipid-lowering drugs (including lipid lowering dietary supplements of food additives) within the last 4 weeks.
- •Diabetes mellitus, defined as glycosylated hemoglobin (HbA1C) above the upper limit of normal (ULN).
- •Uncontrolled arterial hypertension (\>160/100mm Hg).
- •Subjects considered to be unstable (event within 12 weeks) by the investigator after the following events: a myocardial infarction, unstable angina, myocardial revascularisation (PTCA, CABG surgery or another revascularisation procedure) or a transient ischaemic attack (TIA) or stroke.
- •Significant arrythmias or conduction disturbances.
- •Congestive heart failure (NYHA classes III or IV).
- •Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have positive serum pregnancy test (a serum beta-human chorionic gonadotropin analysis).
- •History of homozygous familial hypercholesterolaemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia).
Outcomes
Primary Outcomes
Change in renal plasma flow from baseline in response to L-NMMA infusion after 6 weeks treatment with rosuvastatin.
Secondary Outcomes
- Change in renal plasma flow from baseline in response to L-NMMA infusion after 3 days treatment with rosuvastatin.